Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
ReplyLetter

Drs. Mavragani and Moutsopoulos reply

CLIO P. MAVRAGANI and HARALAMPOS M. MOUTSOPOULOS
The Journal of Rheumatology January 2020, 47 (1) 158; DOI: https://doi.org/10.3899/jrheum.190837
CLIO P. MAVRAGANI
Department of Physiology, School of Medicine, National and Kapodistrian University of Athens;
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kmauragan@med.uoa.gr
HARALAMPOS M. MOUTSOPOULOS
Athens Academy, Chair Medical Sciences/Immunology, Athens, Greece.
MD, FRCP, FACP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

We were delighted to read the letter by Killian, et al, which challenges the use of the terms primary and secondary human Sjögren syndrome (SS) even in experimental animal models of SS1. These terms were coined almost 40 years ago on the basis of a study that revealed clinical, immunologic, and genetic differences among patients expressing sicca manifestations alone and patients with rheumatoid arthritis (RA) and SS. Despite the lack of appropriate studies, the rheumatology community expanded the term secondary SS to include all patients with autoimmune disorders who expressed sicca manifestations. Of note, subsequent reports on patients with systemic lupus erythematosus (SLE) or scleroderma and sicca features did not confirm observations similar to those seen in RA with sicca complaints2.

The MRL/MpJ mouse is an autoimmune strain that develops lacrimal and salivary gland inflammation (dacryoadenitis and sialadenitis) and has been long considered a model for human SS. Two main substrains of MRL/MpJ mice are recognized: the MRL/MpJ-Fas+/Fas+ (MRL/+) and the MRL/MpJ-Faslpr/Faslpr (MRL/lpr). In the latter model, defective Fas mediated apoptosis of lymphocytes in peripheral lymphoid organs occurs as a result of a Fas ligand mutation, and systemic autoimmune disease develops with a wide range of manifestations [e.g., arthritis, glomerulonephritis, vasculitis central nervous system (CNS)/peripheral NS (PNS) inflammation, or massive lymphadenopathy]. In addition to dacryoadenitis and sialadenitis, both strains developed antinuclear antibodies, with the MRL/lpr mice displaying also autoantibodies against Ro/SSA and La/SSB autoantigens3,4.

With this in mind, SS experimental animal models sharing features related to both glandular (diminished salivary and lacrimal secretions) and extraglandular involvement reminiscent of those seen in SLE (e.g., glomerulonephritis, CNS/PNS inflammation) could be erroneously classified as models of “secondary” SS and therefore characterized as “inadequate” for studies investigating the potential efficacy of novel targeted therapies for primary SS1. However, it should be emphasized that these immunological treatment approaches are indeed expected to be effective in SS patients with systemic extraglandular manifestations and excessive immune activation rather than those with local inflammation confined to salivary glands. Moreover, it is worth mentioning that though glomerular involvement is considered mainly an SLE-related rather than an SS-related feature, earlier and more recent works documented the presence of membranoproliferative and membranous glomerulonephritis in patients with “primary” SS5,6. These patients were characterized by the presence of mixed monoclonal cryoglobulins and kidney immunopathology revealing predominant tissue deposition of IgM5. Peripheral neuropathy is another well-known manifestation of primary SS7, which together with glomerulonephritis, lymphadenopathy, and autoantibodies against Ro/SSA and La/SSB autoantigens, among other manifestations, has been shown to be highly predictive for lymphoma development in these patients8,9. The MRL/MpJ experimental animal model is an excellent model for the evaluation of therapeutic modalities because in addition to sicca manifestations, the model expresses extensive lymphoproliferation affecting parenchymal organs3. Unfortunately, at present, management of SS is mainly limited to secretagogues and excretion replacement, while immunosuppressive agents are efficacious neither for alleviation of SS features nor for the prevention of disease progression10.

REFERENCES

  1. 1.↵
    1. Killian M,
    2. Batteux F,
    3. Paul S
    . The MRL/lpr mouse model: an important animal model for systemic Sjögren syndrome and polyautoimmunity. J Rheumatol 2020;47:157.
    OpenUrlFREE Full Text
  2. 2.↵
    1. Mavragani CP,
    2. Moutsopoulos HM
    . Primary versus secondary Sjögren syndrome: is it time to reconsider these terms? J Rheumatol 2019;46:665–6.
    OpenUrlFREE Full Text
  3. 3.↵
    1. Watanabe-Fukunaga R,
    2. Brannan CI,
    3. Copeland NG,
    4. Jenkins NA,
    5. Nagata S
    . Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992;356:314–7.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Lavoie TN,
    2. Lee BH,
    3. Nguyen CQ
    . Current concepts: mouse models of Sjögren’s syndrome. J Biomed Biotechnol 2011;2011:549107.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Moutsopoulos HM,
    2. Balow JE,
    3. Lawley TJ,
    4. Stahl NI,
    5. Antonovych TT,
    6. Chused TM
    . Immune complex glomerulonephritis in sicca syndrome. Am J Med 1978;64:955–60.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Goules AV,
    2. Tatouli IP,
    3. Moutsopoulos HM,
    4. Tzioufas AG
    . Clinically significant renal involvement in primary Sjögren’s syndrome: clinical presentation and outcome. Arthritis Rheum 2013;65:2945–53.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Pavlakis PP,
    2. Alexopoulos H,
    3. Kosmidis ML,
    4. Mamali I,
    5. Moutsopoulos HM,
    6. Tzioufas AG,
    7. et al.
    Peripheral neuropathies in Sjögren’s syndrome: a critical update on clinical features and pathogenetic mechanisms. J Autoimmun 2012;39:27–33.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Skopouli FN,
    2. Dafni U,
    3. Ioannidis JP,
    4. Moutsopoulos HM
    . Clinical evolution, and morbidity and mortality of primary Sjögren’s syndrome. Semin Arthritis Rheum 2000;29:296–304.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Fragkioudaki S,
    2. Mavragani CP,
    3. Moutsopoulos HM
    . Predicting the risk for lymphoma development in Sjogren syndrome: an easy tool for clinical use. Medicine 2016;95:e3766.
    OpenUrl
  10. 10.↵
    1. Mavragani CP,
    2. Moutsopoulos HM
    . Conventional therapy of Sjogren’s syndrome. Clin Rev Allergy Immunol 2007;32:284–91.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 47, Issue 1
1 Jan 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Drs. Mavragani and Moutsopoulos reply
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Drs. Mavragani and Moutsopoulos reply
CLIO P. MAVRAGANI, HARALAMPOS M. MOUTSOPOULOS
The Journal of Rheumatology Jan 2020, 47 (1) 158; DOI: 10.3899/jrheum.190837

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Drs. Mavragani and Moutsopoulos reply
CLIO P. MAVRAGANI, HARALAMPOS M. MOUTSOPOULOS
The Journal of Rheumatology Jan 2020, 47 (1) 158; DOI: 10.3899/jrheum.190837
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • REFERENCES
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • The Journal of Rheumatology: A Strong Supporter of Pediatric Rheumatology
  • Cervical Cancer Screening Is a Highly Neglected Procedure Among Women With Systemic Lupus Erythematosus
  • Considerable Uncertainty About the Burden of Gout in the Middle East and North Africa Region
Show more Letter

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire